SWP
RPRX icon

Strategic Wealth Partners’s Royalty Pharma RPRX Stock Holding History

Strategic Wealth Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-259
Closed -$9.14K – 1546
2025
Q3 		$9.14K Buy
+259
New +$9.38K ﹤0.01% 914

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Strategic Wealth Partners's RPRX Position: Q4 2025 in Review

Strategic Wealth Partners sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 259 shares — an estimated $9.14K sold.

Strategic Wealth Partners first reported a position in RPRX in Q3 2025 and held it in 1 quarter. The position peaked at $9.14K in Q3 2025. 540 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • Strategic Wealth Partners reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • Strategic Wealth Partners sold 259 Royalty Pharma shares in Q4 2025, an estimated $9.14K.
  • Strategic Wealth Partners first reported a position in Royalty Pharma in Q3 2025 and held it in 1 quarter.
  • Strategic Wealth Partners's Royalty Pharma position peaked at $9.14K in Q3 2025.
  • 540 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Strategic Wealth Partners's 13F filing for Q4 2025, filed 12 May 2026.